Aeterna Zentaris Inc. (NASDAQ:AEZS) rose 2.1% on Tuesday . The company traded as high as $3.45 and last traded at $3.43, with a volume of 67,792 shares trading hands. The stock had previously closed at $3.36.

AEZS has been the subject of a number of research reports. Maxim Group reiterated a “buy” rating and set a $11.00 target price on shares of Aeterna Zentaris in a research note on Wednesday, June 15th. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Aeterna Zentaris in a research note on Sunday, July 10th. Zacks Investment Research upgraded shares of Aeterna Zentaris from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a research note on Monday, August 15th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $9.00 target price on shares of Aeterna Zentaris in a research note on Tuesday, August 23rd.

The stock’s 50 day moving average price is $3.56 and its 200 day moving average price is $3.56. The firm’s market capitalization is $33.69 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Aeterna Zentaris (NASDAQ:AEZS) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.82) by $0.11. Aeterna Zentaris had a negative net margin of 5,871.45% and a negative return on equity of 241.78%. On average, analysts forecast that Aeterna Zentaris Inc. will post ($2.61) earnings per share for the current year.

A hedge fund recently raised its stake in Aeterna Zentaris stock. Renaissance Technologies LLC raised its position in shares of Aeterna Zentaris Inc. (NASDAQ:AEZS) by 5.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 516,833 shares of the biopharmaceutical company’s stock after buying an additional 29,000 shares during the period. Renaissance Technologies LLC owned 8.17% of Aeterna Zentaris worth $1,716,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.28% of the company’s stock.

About Aeterna Zentaris

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

5 Day Chart for NASDAQ:AEZS

Receive News & Ratings for Aeterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris Inc. and related companies with's FREE daily email newsletter.